AN2 Therapeutics, Inc. (ANTX) Insider Ownership

Historic Insider Ownership Trends

As of June 12, 2026, the three largest insider holders of ANTX are Capital Management, L.P. Ra (TenPercentOwner, 5.14Mn shares), Capital Management, L.P. Ra (TenPercentOwner, 3.77Mn shares), Braden Michael Leonard (TenPercentOwner, 3.02Mn shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares (Direct) Shares (Indirect) Report Date
Joseph S Zakrzewski - 0 405,880 19 Jan, 2024
Capital Management, L.P. Ra - 0 5,135,683 22 Aug, 2023
Braden Michael Leonard - 0 3,017,432 16 Jun, 2025
Sanjay Chanda Chief Development Officer 118,823 0 23 Feb, 2026
Global Health Technology Fund, L.P. Adjuvant - 1,995,958 377,542 18 Jan, 2024
Margaret M Fitzpatrick - 8,610 0 29 May, 2025
Eric Easom Chief Executive Officer 0 1,065,766 18 Nov, 2024
Lucy Day Chief Financial Officer 118,363 0 23 Feb, 2026
Paul Eckburg Chief Medical Officer 51,416 0 18 Mar, 2024
Kabeer Aziz - 0 2,473,500 16 Nov, 2023
Robin Shane Readnour - 0 652,573 10 Dec, 2024
Patricia A. Martin - 18,097 0 10 Apr, 2026
Kevin Michael Krause Chief Strategy Officer 31,914 0 29 Mar, 2024
Gilbert Lynn Marks - 79,084 0 10 Apr, 2026
Joshua M Eizen Chief Legal Officer 207,499 0 23 Feb, 2026
Stephen David Prior Chief Strategy Officer 59,086 0 07 Jan, 2026
Sarah Joanne Williams Principal Accounting Officer 66,848 0 05 Mar, 2026

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
10 Apr, 2026 Patricia A. Martin Common Stock A 1,192 $0.00 18,097 D A
10 Apr, 2026 Gilbert Lynn Marks Common Stock A 3,775 $0.00 79,084 D A
10 Apr, 2026 Kabeer Aziz Common Stock A 3,775 $0.00 56,254 D A
10 Apr, 2026 Kabeer Aziz Common Stock A 3,775 $0.00 56,254 D A
10 Apr, 2026 Gilbert Lynn Marks Common Stock A 3,775 $0.00 79,084 D A
19 Mar, 2026 Robin Shane Readnour Stock Option (right to buy) A 20,724 - 20,724 D A
19 Mar, 2026 Gilbert Lynn Marks Stock Option (right to buy) A 10,665 - 10,665 D A
19 Mar, 2026 Sanjay Chanda Stock Option (right to buy) A 66,000 - 66,000 D A
19 Mar, 2026 Joseph S Zakrzewski Stock Option (right to buy) A 99,999 - 99,999 D A
19 Mar, 2026 Melvin K Spigelman Stock Option (right to buy) A 16,941 - 16,941 D A
19 Mar, 2026 Sanjay Chanda Stock Option (right to buy) A 66,000 - 66,000 D A
19 Mar, 2026 Lucy Day Stock Option (right to buy) A 73,665 - 73,665 D A
19 Mar, 2026 Gilbert Lynn Marks Stock Option (right to buy) A 10,665 - 10,665 D A
19 Mar, 2026 Eric Easom Stock Option (right to buy) A 249,999 - 249,999 D A
19 Mar, 2026 Kabeer Aziz Stock Option (right to buy) A 20,724 - 20,724 D A
19 Mar, 2026 Kabeer Aziz Stock Option (right to buy) A 20,724 - 20,724 D A
19 Mar, 2026 Robin Shane Readnour Stock Option (right to buy) A 20,724 - 20,724 D A
19 Mar, 2026 Melvin K Spigelman Stock Option (right to buy) A 16,941 - 16,941 D A
19 Mar, 2026 Joshua M Eizen Stock Option (right to buy) A 92,000 - 92,000 D A
19 Mar, 2026 Stephanie Wong Stock Option (right to buy) A 24,999 - 24,999 D A